close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

8.850 +0.090 (+1.03%)
Delayed Quote Updated: 10:21 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sagimet Biosciences Inc. - Series A Common Stock

< Previous 1 2 3 Next >
News headline image
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch ↗
Sagimet Biosciences (NASDAQ:SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor... 
Via MarketBeat
News headline image
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data ↗
Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following... 
Via MarketBeat
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study ↗
Via Stocktwits
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Why Sagimet Biosciences Stock Is Soaring Today ↗
The biopharma company confirmed it's still aiming at the United States' acne-treatment market. 
Via The Motley Fool
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Sagimet Biosciences Tops Q2 EPS Forecast ↗
Via The Motley Fool
News headline image
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps ↗
Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Monday's session. ↗
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024 ↗
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
What's Going On With Sagimet Biosciences Stock On Thursday? ↗
Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress. 
Via Benzinga
News headline image
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? ↗
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.